John Langlands
Chief Operating Officer Rakovina Therapeutics, Inc.
John Langlands is Principal at Langlands & Associates Consulting and Chief Operating Officer at Rakovina Therapeutics, with extensive experience across clinical development, clinical operations, and regulatory affairs. His expertise includes the development and management of compassionate use and early access programs, alongside the design and delivery of clinical trials. Previously Head of Clinical Operations at Kintara Therapeutics, John oversaw both clinical trials and the company’s expanded access program. He also brings experience supporting regulatory submissions to the FDA, MHRA, Health Canada, and TGA.
Seminars
Wednesday 24th March 2027
Using Retrospective AI Analysis to Unlock Insights from Expanded Access Program Data
4:30 pm
- Exploring how retrospective AI analysis can be applied to data collected through Expanded Access Programs, identifying patterns and insights across existing program datasets
- Sharing a real-world biotech case study on the approach, including what the analysis revealed and the potential for AI to strengthen how EAP data is interpreted and used
